Related Experiment Video
Updated: Jun 14, 2026
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer
Sean P Dineen1, Christina L Roland, Rachel Greer
1Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, TX, USA.
Abstract:
Failure of chemotherapy in the treatment of pancreatic cancer is often due to resistance to therapy-induced apoptosis. A major mechanism for such resistance is the expression and activity of inhibitors of apoptosis proteins (IAP). Smac (second mitochondria-derived activator of caspase) is a mitochondrial protein that inhibits IAPs. We show that JP1201, a Smac mimetic, is a potent enhancer of chemotherapy in robust mouse models of pancreatic cancer. Combination of JP1201 with gemcitabine reduced primary and metastatic tumor burden in orthotopic xenograft and syngenic tumor models, induced regression of established tumors, and prolonged survival in xenograft and transgenic models of pancreatic cancer. The effect of JP1201 was phenocopied by XIAP small interfering RNA in vitro and correlated with elevated levels of tumor necrosis factor alpha protein in vivo. The continued development of JP1201 and other strategies designed to enhance therapy-induced apoptosis in pancreatic cancer is warranted.
Insights
JP1201, a Smac mimetic, enhances chemotherapy by overcoming resistance to apoptosis in pancreatic cancer. Combining JP1201 with gemcitabine reduced tumors, induced regression, and prolonged survival in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Pancreatic cancer chemotherapy often fails due to resistance to apoptosis.
- Inhibitors of Apoptosis Proteins (IAP) are key mediators of this resistance.
- Smac (second mitochondria-derived activator of caspase) antagonizes IAPs.
Purpose of the Study:
- To evaluate JP1201, a Smac mimetic, as a chemotherapy enhancer for pancreatic cancer.
- To investigate the mechanisms underlying JP1201's efficacy.
Main Methods:
- Utilized robust mouse models of pancreatic cancer (orthotopic xenograft, syngenic, transgenic).
- Administered JP1201 in combination with gemcitabine.
- Assessed tumor burden, tumor regression, survival, and molecular markers (XIAP, TNF-alpha).
Main Results:
- JP1201 significantly enhanced gemcitabine efficacy in reducing primary and metastatic tumor burden.
- Combination therapy induced regression of established tumors and prolonged survival.
- JP1201's effects were mimicked by XIAP inhibition and correlated with increased TNF-alpha.
Conclusions:
- JP1201 is a potent enhancer of chemotherapy in pancreatic cancer preclinical models.
- Targeting IAP-mediated apoptosis resistance with Smac mimetics is a promising therapeutic strategy.
- Further development of JP1201 and similar agents for pancreatic cancer is warranted.
